巴西SARS-CoV-2感染严重程度的预测因素:一项随机对照试验的事后分析
该研究基于巴西ChAdOx1 nCoV-19疫苗随机对照试验的事后分析,纳入10416名参与者,其中1790例核酸扩增试验阳性COVID-19感染,63例需住院。校正人口学和临床因素后,BMI较高和糖尿病与更严重感染相关,年龄和BMI较高与住院风险增加相关。完全接种亚组(n=841)中仅年龄较大预测住院。
要点
- BMI较高(OR=1.06,95%CI 1.01-1.10)和糖尿病(OR=3.67,95%CI 1.59-8.07)与更严重感染相关。
- 年龄(OR=1.06,95%CI 1.03-1.08)和BMI(OR=1.10,95%CI 1.05-1.16)较高与住院风险增加相关。
- 完全接种亚组(n=841)中仅年龄较大预测住院(OR=1.07,95%CI 1.03-1.12)。
核心结论
- 未接种疫苗且BMI较高和糖尿病者面临更严重COVID-19结局风险,接种疫苗减轻了该风险。
研究设计与样本
- 巴西ChAdOx1 nCoV-19疫苗大规模随机对照试验的事后分析,参与者1:1随机接受疫苗或对照组。
- 共纳入10416名参与者,其中1790例核酸扩增试验阳性COVID-19感染,63例需住院。
- 部分参与者在第二剂疫苗接种后28天测量抗刺突抗体反应和血清中和活性。
- 采用逻辑回归模型校正人口学和临床因素,探索与COVID-19感染严重程度和住院相关的因素。
主要发现
- 更严重感染与较高BMI(OR=1.06,95%CI 1.01-1.10,p=0.01)和糖尿病(OR=3.67,95%CI 1.59-8.07,p=0.003)相关。
- 住院风险随年龄(OR=1.06,95%CI 1.03-1.08,p<0.001)和BMI(OR=1.10,95%CI 1.05-1.16,p<0.001)增加而升高。
- 末次接种后超过180天,更严重感染和住院风险增加。
- 完全接种亚组(n=841)中,仅年龄较大预测住院(OR=1.07,95%CI 1.03-1.12,p<0.001)。
- 两剂疫苗的血清学反应随年龄增长而减弱。
临床怎么用
- 未接种疫苗且BMI较高和糖尿病者面临更严重COVID-19结局风险,接种疫苗减轻了该风险。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To identify demographic, clinical and immunological factors associated with adverse COVID-19 outcomes. METHODS: A large randomised controlled trial of ChAdOx1 nCoV-19 was undertaken in Brazil. Participants were randomised 1:1 either to receive ChAdOx1 nCov-19 or to a control group. COVID-19 infections were confirmed by nucleic acid amplification test (NAAT) and classified using the WHO clinical progression scale. Anti-spike antibody responses and serum neutralising activity were measured 28 days after second vaccination in some participants. Exploratory analyses were conducted into factors associated with COVID-19 infection severity and hospitalisation, using logistic regression models adjusted for demographic and clinical factors. RESULTS: 10,416 participants were enrolled; 1790 had NAAT-positive COVID-19 infection; 63 cases required hospitalisation. More severe infection was associated with greater body-mass index (BMI) (odds ratio [OR] = 1.06 [95 %CI: 1.01-1.10], p = 0.01) and diabetes (OR = 3.67 [1.59-8.07], p = 0.003). Hospitalisation risk increased with greater age (OR = 1.06 [1.03-1.08], p < 0.001) and BMI (OR = 1.10 [1.05-1.16], p < 0.001). More severe infection and hospitalisation risks increased >180 days after last vaccination. In the fully vaccinated subgroup (n = 841), only greater age predicted hospitalisation (OR = 1.07 [1.03-1.12], p < 0.001). Serological responses to two vaccine doses diminished with age. CONCLUSIONS: Unvaccinated individuals with high BMI and diabetes risked more severe COVID-19 outcomes. Vaccination mitigated this risk. CLINICAL TRIAL REGISTRATION NUMBER: NCT04536051.
引用
- Conlin K, Jenkin D, de Whalley P, et al. Predictors of severity of SARS-CoV-2 infections in Brazil: Post hoc analyses of a randomised controlled trial. Vaccine. 2024. PMID: 39675209. doi:10.1016/j.vaccine.2024.126582
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。